Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
J Pharmacol Exp Ther
; 352(3): 579-89, 2015 Mar.
Article
in En
| MEDLINE
| ID: mdl-25576074
ABSTRACT
Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family of serine/threonine kinases, is a key regulator of multiple steps in mitosis. Here we report on the pharmacological profile of volasertib, a potent and selective Plk inhibitor, in multiple preclinical models of acute myeloid leukemia (AML) including established cell lines, bone marrow samples from AML patients in short-term culture, and subcutaneous as well as disseminated in vivo models in immune-deficient mice. Our results indicate that volasertib is highly efficacious as a single agent and in combination with established and emerging AML drugs, including the antimetabolite cytarabine, hypomethylating agents (decitabine, azacitidine), and quizartinib, a signal transduction inhibitor targeting FLT3. Collectively, these preclinical data support the use of volasertib as a new therapeutic approach for the treatment of AML patients, and provide a foundation for combination approaches that may further improve and prolong clinical responses.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pteridines
/
Leukemia, Myeloid, Acute
/
Proto-Oncogene Proteins
/
Protein Serine-Threonine Kinases
/
Cell Cycle Proteins
/
Protein Kinase Inhibitors
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
J Pharmacol Exp Ther
Year:
2015
Type:
Article